Cantor Fitzgerald initiated coverage of Context Therapeutics (CNTX) with an Overweight rating. Context is an under-the-radar oncology company developing three T-cell engagers, and as the company has been in execution mode, it is now approaching multiple data inflection points in 2026, the analyst tells investors in a research note. Lead program, CTIM-76, could prove to be a viable drug in ovarian cancer, the firm argues.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX: